SCHEMBL25812244

SCHEMBL25812244

CCC(C)NC(=O)c1nc2c(Cl)ccc(Cl)c2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
ERCC1 P07992 1/20 0.40
FEN1 P39748 1/20 0.40
ERCC4 Q92889 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758835 0.86 ALOX15 (0.42) LMNASMN1; SMN2POLB
SCHEMBL25758898 0.75 PDE4A (0.43) ALDH1A1HPGDKDM4EMAPTSMN1; SMN2
SCHEMBL24019965 0.75 ALPL (0.39) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL23824446 0.75 KDM4E (0.41) LMNAALDH1A1KDM4EDYRK1A
SCHEMBL11390105 0.75 LMNA (0.44) LMNAALDH1A1HPGDGAAMEN1
SCHEMBL25768666 0.73 NPC1 (0.45) LMNAALDH1A1HPGDGAAMEN1
SCHEMBL24190232 0.73 F2 (0.40) LMNAALDH1A1HPGDGAAKMT2A
SCHEMBL25789987 0.70 HTT (0.66) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL161197 0.69 JAK2 (0.43) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL25811983 0.68 KDM4E (0.48) LMNAALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV LMNA 2202/4885ALDH1A1 1863/4885HPGD 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.